ABCA3 and B-cell non-Hodgkin lymphoma: Moreover, it has been reported that LCEVs efficiently extrude drugs and can drive drug resistance in aggressive B-cell lymphomas via the ATP-transporter A3-mediated mechanism (ABCA3) [105].